Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

ClinicalTrials.gov ID: NCT01502124

Public ClinicalTrials.gov record NCT01502124. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.

Study identification

NCT ID
NCT01502124
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
78 participants

Conditions and interventions

Eligibility (public fields only)

Age range
3 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 8, 2001 (Actual)
Primary completion
Mar 5, 2003 (Actual)
Completion
Mar 5, 2003 (Actual)
Last update posted
Feb 28, 2017

2001 – 2003

United States locations

U.S. sites
21
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Novo Nordisk Investigational Site Los Angeles California 90027 —
Novo Nordisk Investigational Site Los Angeles California 90048-1869 —
Novo Nordisk Investigational Site Wilmington Delaware 19899 —
Novo Nordisk Investigational Site Washington D.C. District of Columbia 20010 —
Novo Nordisk Investigational Site Gainesville Florida 32608 —
Novo Nordisk Investigational Site Miami Florida 33155 —
Novo Nordisk Investigational Site Orlando Florida 32806-1101 —
Novo Nordisk Investigational Site Tampa Florida 33607 —
Novo Nordisk Investigational Site Atlanta Georgia 30342 —
Novo Nordisk Investigational Site Chicago Illinois 60612 —
Novo Nordisk Investigational Site Chicago Illinois 60614 —
Novo Nordisk Investigational Site Wichita Kansas 67226 —
Novo Nordisk Investigational Site Lexington Kentucky 40536-0284 —
Novo Nordisk Investigational Site Louisville Kentucky 40202 —
Novo Nordisk Investigational Site Worcester Massachusetts 01655 —
Novo Nordisk Investigational Site Manhasset New York 11030 —
Novo Nordisk Investigational Site Akron Ohio 44308-1062 —
Novo Nordisk Investigational Site Hershey Pennsylvania 17033 —
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15212 —
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224 —
Novo Nordisk Investigational Site Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01502124, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 28, 2017 · Synced Oct 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01502124 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →